tiprankstipranks
Trending News
More News >
Alembic Limited (IN:ALEMBICLTD)
:ALEMBICLTD
India Market
Advertisement

Alembic Limited (ALEMBICLTD) AI Stock Analysis

Compare
3 Followers

Top Page

IN:ALEMBICLTD

Alembic Limited

(ALEMBICLTD)

Select Model
Select Model
Select Model
Neutral 68 (OpenAI - 4o)
Rating:68Neutral
Price Target:
₹126.00
▲(26.04% Upside)
The overall score reflects strong financial health and undervaluation, counterbalanced by mixed technical trends and concerns over the sustainability of profit margins. The absence of earnings call data limits the assessment of future outlook.

Alembic Limited (ALEMBICLTD) vs. iShares MSCI India ETF (INDA)

Alembic Limited Business Overview & Revenue Model

Company DescriptionAlembic Limited (ALEMBICLTD) is a diversified company engaged in the pharmaceutical and biotechnology sectors. Founded in India, the company operates primarily in the development, manufacturing, and marketing of a wide range of pharmaceutical products, including generics and active pharmaceutical ingredients (APIs). Alembic Limited is also involved in research and development initiatives aimed at innovating new drug formulations and therapies, catering to both domestic and international markets.
How the Company Makes MoneyAlembic Limited generates revenue primarily through the sale of its pharmaceutical products, which include generic medications and APIs. The company engages in both direct sales and distribution partnerships to reach a broad customer base, including hospitals, pharmacies, and healthcare providers. Additionally, Alembic Limited benefits from licensing agreements and collaborations with other pharmaceutical companies for research and development projects, which can yield royalty income and shared profits. The company also focuses on expanding its market presence in global markets, which contributes to its revenue growth through exports and international sales.

Alembic Limited Financial Statement Overview

Summary
Alembic Limited shows strong revenue growth and profitability with a healthy balance sheet. The unusually high net profit margin suggests potential one-time gains, raising concerns about sustainability despite improved cash flow management.
Income Statement
85
Very Positive
Alembic Limited shows strong revenue growth with a 50.8% increase from 2024 to 2025, demonstrating robust expansion in the specialty and generic drug market. The gross profit margin is healthy at 68.8% for 2025, reflecting effective cost management. However, the net profit margin is unusually high at 140%, likely due to one-time gains or accounting adjustments, which could be an anomaly. The EBIT margin of 37.4% and EBITDA margin of 76% indicate strong core operational profitability.
Balance Sheet
78
Positive
The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.006 in 2025, signifying low leverage and financial risk. The equity ratio stands robust at 93.4%, showing a strong capital structure. Return on Equity (ROE) is high at 13.3%, driven by substantial net income, but this figure may be inflated by non-recurring items. Overall, the balance sheet reflects financial stability, though the high net income may not be sustainable.
Cash Flow
70
Positive
The cash flow statement reveals a positive shift in free cash flow, from negative in 2024 to positive in 2025, indicating improved cash generation. The operating cash flow to net income ratio of 0.28 suggests moderate cash conversion efficiency. The free cash flow to net income ratio of 0.11 is low, hinting at potential cash flow challenges despite high net income figures. The company shows progress in cash flow management, but sustainability remains a concern.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.21B2.22B1.57B1.18B713.69M678.37M
Gross Profit1.52B1.53B872.46M702.07M404.50M392.74M
EBITDA1.69B1.69B1.12B939.86M1.03B213.43M
Net Income3.17B3.11B2.69B1.91B2.22B3.43B
Balance Sheet
Total Assets0.0025.03B23.29B22.05B26.32B24.09B
Cash, Cash Equivalents and Short-Term Investments582.70M582.80M129.05M464.09M270.77M225.14M
Total Debt0.00144.50M91.49M0.000.002.77M
Total Liabilities-23.39B1.64B1.43B1.27B1.35B1.12B
Stockholders Equity23.39B23.39B21.86B20.78B24.97B22.97B
Cash Flow
Free Cash Flow0.00356.00M-336.03M130.35M-535.60M-496.37M
Operating Cash Flow0.00863.70M226.87M388.52M-177.47M-21.82M
Investing Cash Flow0.00-265.80M258.36M72.96M188.48M-348.69M
Financing Cash Flow0.00-583.40M-481.94M-463.88M-58.16M-153.62M

Alembic Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price99.97
Price Trends
50DMA
103.87
Negative
100DMA
108.45
Negative
200DMA
106.79
Negative
Market Momentum
MACD
-1.65
Positive
RSI
44.34
Neutral
STOCH
38.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALEMBICLTD, the sentiment is Neutral. The current price of 99.97 is below the 20-day moving average (MA) of 101.45, below the 50-day MA of 103.87, and below the 200-day MA of 106.79, indicating a bearish trend. The MACD of -1.65 indicates Positive momentum. The RSI at 44.34 is Neutral, neither overbought nor oversold. The STOCH value of 38.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ALEMBICLTD.

Alembic Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
₹639.72B18.860.36%7.76%-2.84%
72
Outperform
₹667.41B29.210.81%4.49%11.22%
68
Neutral
₹25.67B8.112.40%28.84%13.01%
60
Neutral
₹184.28B30.561.17%8.20%-4.26%
60
Neutral
₹326.29B41.910.31%11.49%35.00%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
₹525.25B69.690.13%10.99%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:ALEMBICLTD
Alembic Limited
99.97
-24.56
-19.72%
IN:ALKEM
Alkem Laboratories Ltd.
5,581.95
-517.24
-8.48%
IN:APLLTD
Alembic Pharmaceuticals Limited
937.50
-191.09
-16.93%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,101.45
-351.89
-24.21%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
1,861.25
150.20
8.78%
IN:IPCALAB
IPCA Laboratories Limited
1,286.35
-322.90
-20.07%

Alembic Limited Corporate Events

Alembic Limited Updates Registrar Contact Details
Apr 18, 2025

Alembic Limited announced a change in the email and website address of its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. This update is part of a continued effort to streamline communication and improve service efficiency for shareholders, reflecting the company’s commitment to maintaining effective stakeholder relations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 26, 2025